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Introduction
Chronic cough, defined as cough lasting for  8 weeks,
is one of the most common symptoms of medical impor-
tance, and the prevalence in the community is 9–33%.1 A
subgroup of patients suffer from the debilitating and dis-
tressing disorder of cough syncope, which is difficult to
effectively manage and treat. The approach in clinic is to
determine an underlying etiology for cough syncope and
to treat the underlying cause with the hope that cough
syncopal episodes will improve. In a situation in which
cough syncope is idiopathic, current treatments are ad-
dressed directly at suppressing the sensory cough reflex.
These include codeine, dextromethorphan, levodro-
propizine, moguisteine, local anesthetics (eg, lidocaine,
mepivacaine) and low-dose morphine, yet the effects of
these therapies are rather disappointing in alleviating this
condition in patients. Indeed, there is a real unmet need for
effective treatments in patients suffering from cough.2 It
has been suggested that chronic cough is a neuropathic
disorder,3 and gabapentin, a treatment for neuropathic pain,
has recently shown evidence of efficacy. A recent random-
ized controlled trial demonstrated an improvement in
cough-specific quality of life when gabapentin was used at
high doses of up to 1,800 mg.4 This teaching case for
health-care professionals describes the clinical assessment
and medical management of a patient with cough syncope
and highlights the effectiveness of low-dose gabapentin in
controlling our patient’s difficult-to-manage cough.
Case Summary
A 63-y-old man was referred to the Royal Brompton
Hospital Cough Clinic with a chronic nonproductive cough
of 8 y. His cough was socially distressing; in particular, he
noticed his cough was triggered at mealtimes, which had
led him to eat in isolation from his family. Of significance,
he had experienced 2 sudden cough-associated syncopal
episodes leading to emergency hospital visits for scalp
suturing. These events had precipitated his referral to our
specialist cough clinic. On assessment, he had no other
respiratory symptoms and had never smoked. Medical re-
view noted no symptoms of dyspepsia or postnasal drip,
and he did not report a history of hay fever, asthma, ec-
zema, or occupational exposure to chemical irritants. He
had been treated for hypertension by his family practitio-
ner with the angiotensin-converting enzyme inhibitor enal-
april, which had subsequently been changed to an alterna-
tive antihypertensive drug, but without any resolution of
his cough.
On medical examination, there were no cardiovascular,
respiratory, neurological, or gastrointestinal abnormalities
noted. His pulmonary investigations of spirometry, chest
radiography, chest computed tomography, and endoscopic
bronchoscopy were all normal. Bronchial hyper-reactivity
testing with inhaled histamine was not significant, and
overnight oximetry did not suggest obstructive sleep ap-
nea. Neurological investigation undertaken with magnetic
resonance imaging of the brain showed no structural ab-
normality, specifically no Arnold-Chiari malformation.
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Cardiovascular testing involving Holter monitoring for
rhythm abnormalities was normal, and his echocardiogram
did not identify any structural or functional dysfunction of
the heart. Carotid artery ultrasound showed no arterial
stenosis. Autonomic investigations, including the Valsalva
maneuver, mental arithmetic testing, and cutaneous cold
pressor testing, were performed to assess vagal and sym-
pathetic responsiveness. Situational cardiovascular tilt test-
ing detected an initial fall in blood pressure during cough-
ing and then an overshoot after coughing.
Our patient received several treatment trials to try to
manage his underlying cough and associated syncope. In
relation to his mealtime-induced cough, he was treated
with 3 months of a high-dose proton pump inhibitor (40 mg
of lansoprazole daily) with little improvement in his cough.
His cough symptom was also unresponsive to a variety of
pulmonary and allergy treatments, including oral antihis-
tamines (chlorpheniramine), inhaled high-dose long-acting
-agonist and corticosteroid combination treatment (for-
moterol and beclometasone dipropionate), and oral pred-
nisolone. Codeine linctus, an opioid sometimes used to
suppress a dry irritating cough in intractable situations,
alleviated his acute cough episodes, but only for a few
hours. Most significantly, his startling cough syncopal ep-
isodes did not resolve with any treatment. For this reason,
we decided to treat our patient with low-dose gabapentin
in light of recent data on the efficacy of gabapentin in
chronic idiopathic cough.4 Remarkably,within a fewweeks,
his cough came under complete control with only 200 mg
of gabapentin daily. His quality of life dramatically im-
proved such that he was able to dine with his family. He
experienced no adverse effects, yet notably, when he omit-
ted gabapentin for 3 d, his cough reappeared. Most impor-
tantly, he experienced no cough-related syncopal episodes.
Discussion
The production of cough can result from voluntary or
involuntary physiological responses. The involuntary (or
reflex cough) response is triggered by cough receptors
located in the airway bifurcation, larynx, and distal esoph-
agus.5 Cough receptors are connected to afferent nerve
fibers that originate from the vagus nerve and conduct
signals to the nucleus tractus solitarius in the brainstem
and then on to the central cough center, which transmits
the signals into an efferent cough response.6 There are 3
types of cough receptors, defined by their conductive prop-
erties: (1) rapidly adapting receptors, (2) slowly adapting
receptors, and (3) C-fibers.7,8 Rapidly adapting receptors
are sensitive to cigarette smoke, acid and alkaline chemi-
cals, and mechanical stimulation from chronic lung dis-
eases.9,10 In contrast, C-fibers are stimulated by irritants
such as bradykinin (a mediator released during inflamma-
tion) and capsaicin (a vanilloid extract of peppers).11 Tran-
sient receptor potential vanilloid-1 (TRPV-1) is a receptor
for capsaicin that is found on rapidly adapting receptors
and C-fibers. It also responds to heat, acid, bradykinin,
arachidonic acid derivatives, and adenosine triphosphate.12
TRPV-1 has been shown to be increased in patients with
chronic cough.13 Furthermore, patients with chronic cough
have an increased cough sensitivity to inhaled capsaicin
compared with normal subjects.14 Consequently, there is
current interest in targeting the vanilloid receptor channels
as a potential treatment for patients with chronic cough.15
Cough is a common respiratory symptom and is often
the main reason for presentation to pulmonologists and
respiratory physicians.16 Cough-associated syncope in par-
ticular is an alarming and debilitating condition for pa-
tients. It is a difficult-to-manage condition and is often
associated with traumatic consequences for sufferers; in
our patient, cough syncope led to scalp-suturing events. It
is therefore important for health-care professionals to me-
ticulously assess and investigate for an underlying etio-
logical cause of cough syncope, paying particular attention
to the cardiovascular, respiratory, and neurological sys-
tems with the approach that treating the underlying cause
may alleviate these distressing episodes. Indeed, it is
thought that cough may provoke syncope via impaired
cardiac or autonomic blood pressure regulation. Therefore,
the evaluation of cough syncope should consist of assess-
ing sinus arrest, evaluating autonomic regulation, detect-
ing carotid artery stenoses, and identifying abnormalities
in the brain (in particular, structural defects in the cere-
bellum, such as Arnold-Chiari malformation, that can con-
tribute to autonomic dysfunction) (Table 1). Some inves-
tigators have reported a potential pathophysiological
mechanism for cough syncope in that a transient increase
in intrathoracic pressure while coughing leads to reduced
cerebral perfusion and subsequently to a brief loss of con-
sciousness.17,18 Nevertheless, in some cases, the etiologi-
cal cause of cough syncope remains unclear, so patients
are managed with antitussive treatments to directly sup-
press the sensory cough reflex.
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In the clinical management of patients with chronic
cough, a variety of antitussives are used, including opiates
(codeine and morphine), histamine H1 receptor antago-
nists, dextromethorphan, levodropropizine, chlophedianol,
and local anesthetics. The accepted standard antitussive,
codeine, is one of the most widely prescribed medications
for cough. However, multiple trials have demonstrated that
it is poorly effective in controlling cough.19,20 The mech-
anisms by which histone H1 antagonists and dextro-
methorphan affect cough remain unclear. There have been
no placebo-controlled trials for levodropropizine to date.2
Baclofen, a gamma-aminobutyric acid A receptor agonist,
has been shown to inhibit capsaicin-induced cough in an-
imals.21,22 However, human placebo-controlled trials are
required to evaluate the efficacy of the drug. Indeed, there
is an important placebo effect in patients with cough.23
Overall, the failure of current treatments is due to the
complex components of the cough mechanism and a lack
of consistent evidence of efficacy.
In this context, a recent randomized placebo-controlled
trial involving 62 subjects demonstrated a significant im-
provement in cough-specific quality of life when gaba-
pentin was used at high doses of up to 1,800 mg daily for
3 months in comparison with a placebo.4 Gabapentin is a
gamma-aminobutyric acid analog that acts on gamma-
aminobutyric acid B receptors and 22 subunits of volt-
age-dependent calcium channels.24 Gamma-aminobutyric
acid B receptors are expressed in the lungs and are in-
volved in the prevention of bronchospasm, airway micro-
vascular leakage, and cough, and 22 subunits have been
found to be expressed mainly in lung tissues in humans.25
Gabapentin is thought to bind to 2 subunits in the cen-
tral nervous system. Increased laryngeal hypersensitivity
is a recognized finding in patients with chronic cough, and
it has been proposed that gabapentin may act as an anal-
gesic agent in inflammatory or neuropathic cough.26 In-
deed, the effects of the drug on the peripheral nervous
system are supported by its efficacy in sensory neuropa-
thy-associated cough.27
An important consideration with all treatment interven-
tions is adverse effects. In the randomized controlled trial
of Ryan et al,4 high doses of gabapentin (1,800 mg) im-
proved cough-specific quality of life, but 31% of subjects
experienced side effects that required dose reduction or
treatment cessation. The main reported effects were nau-
sea, fatigue, and dizziness. In contrast, lower doses of
gabapentin have been utilized by previous investigators
with good outcome. Mintz and Lee28 described the clinical
outcome of gabapentin in 6 female subjects who were
treated with lower doses of the medication ranging from
100 to 800 mg twice daily. Similar to our patient in this
teaching case, 5 of the 6 subjects in the study showed
either complete resolution or substantial improvement in
cough on low-dose treatment; however, the results from
this study were not conclusive, as only a few female sub-
jects were enrolled. Van de Kerkhove et al29 recently
showed an improvement in cough symptoms with lower
doses of gabapentin (600 mg twice daily). We were able to
treat and completely control our patient’s cough syncope
with a very low dose (200 mg) of gabapentin after numer-
ous standard cough treatments had been tried without any
effect. The effects of gabapentin in improving his quality
of life were clearly evident, and our report presents an
important take-home message to practicing physicians to
consider using smaller initial doses of gabapentin and then
titrating up, particularly as efficacy may be achieved with
a much lower dose compared with the reported clinical
trials. This approach will also potentially minimize any
side effects caused by the drug. In our clinic, our approach
is to prescribe a starting dose of 100 mg of gabapentin
daily and then titrate up by 100 mg daily every 2 weeks
until the patient derives a subjective improvement in cough,
at which point, the dose is maintained.
In summary, our teaching case describes cough syncope
resulting from chronic intractable cough as a debilitating
condition affecting our patient’s quality of life. Our case
illustrates that idiopathic chronic cough can be controlled
at a significantly lower dose of gabapentin compared with
recently published clinical trials, and this is an important
message for health-care professionals. This observation
should provide the basis for further academic research on
investigating the mechanistic effects of the drug at lower
doses. Indeed, the dose of gabapentin necessary to control
chronic cough in the clinic may be quite different and
possibly, as we have shown, lower compared with the
established licensed indicated higher dose used for the
control of neuropathic pain and epilepsy.
Teaching Points
• Cough syncope is a debilitating condition for which there
is currently no effective treatment.
• Respiratory, cardiac, and neurological assessments are
essential to ascertain an underlying etiology.
• The comprehensive evaluation of cough syncope should
include investigation of autonomic function, vascular
carotid artery disorders, structural and functional cardiac
dysfunction, sleep disturbance, and anatomical brain ab-
normalities
• Low-dose gabapentin should be considered in managing
such difficult-to-treat patients.
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